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ABSTRACT
Objectives: Stroke is a major cause of morbidity and
mortality. This study aimed to investigate secular
trends in stroke across the UK.
Design: This study aimed to investigate recent trends in
the epidemiology of stroke in the UK. The study was
a time-trend analysis from 1999 to 2008 within the UK
General Practice Research Database. Outcome measures
were incidence and prevalence of stroke, stroke
mortality, rate of secondary cardiovascular events, and
prescribing of pharmacological therapy for primary and
secondary prevention of cardiovascular disease.
Results: The study cohort included 32151 patients
with a ﬁrst stroke. Stroke incidence fell by 30%, from
1.48/1000 person-years in 1999 to 1.04/1000 person-
years in 2008 (p<0.001). Stroke prevalence increased
by 12.5%, from 6.40/1000 in 1999 to 7.20/1000 in
2008 (p<0.001). 56-day mortality after ﬁrst stroke
reduced from 21% in 1999 to 12% in 2008
(p<0.0001). Prescribing of drugs to control
cardiovascular risk factors increased consistently over
the study period, particularly for lipid lowering agents
and antihypertensive agents. In patients with atrial
ﬁbrillation, use of anticoagulants prior to ﬁrst stroke
did not increase with increasing stroke risk.
Conclusion: Stroke incidence in the UK has decreased
and survival after stroke has improved in the past
10 years. Improved drug treatment in primary care is
likely to be a major contributor to this, with better
control of risk factors both before and after incident
stroke. There is, however, scope for further
improvement in risk factor reduction in high-risk
patients with atrial ﬁbrillation.
BACKGROUND
Stroke is a major cause of morbidity and
mortality in the UK. Around 110000 strokes
occur in England each year,
1 with recent
studies reporting an incidence of between
1.36/1000/year
2 and 1.62/1000/year in
2002e2004.
3 A study in the Scottish Borders
reported a higher crude incidence rate of
2.8/1000/year, which was attributed to the
higher proportion of elderly subjects in the
population.
4 Although deaths from stroke
have fallen in the UK over the past
40 years,
5e7 stroke accounted for around
46500 deaths in England and Wales in 2008
(9% of all deaths).
8
Current UK health policy places great
emphasis on reducing strokes.
9e11 Key to this
is the need for better management of
vascular risk factors, including hypertension,
obesity, high cholesterol, atrial ﬁbrillation
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ARTICLE SUMMARY
Article focus
- Regional UK data have suggested a decline in
stroke incidence, in association with increased
use of preventive treatments and reduction in
cardiovascular risk factors.
- This is the ﬁrst national study to examine recent
trends in stroke incidence and mortality.
Key messages
- In the UK, stroke incidence and stroke mortality
fell consistently between 1999 and 2008.
- This change coincided with a marked increase in
primary care prescription of primary and
secondary cardiovascular prevention therapies.
- Despite these positive ﬁndings, there appears to
be a need for better risk stratiﬁcation as the data
suggest underutilisation of anticoagulation in
patients with atrial ﬁbrillation at high risk of
stroke and lower use of all preventive treatments
in women than in men.
Strengths and limitations of this study
- The General Practice Research Database (GPRD)
is the largest primary care database in the world,
containing the longitudinal records of over 3
million patients.
- We are reliant on the quality of general
practitioner coding in the GPRD dataset. There
may be some coding error and misreporting of
cardiovascular events and risk factors.
- The GPRD contains secondary care data but this
is limited to diagnoses; data on secondary care
prescribing are not available.
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61 1In 2008, NHS Health Check (formerly
called the Vascular Check Programme) was introduced
to identify and manage vascular risk.
12 More recently,
NHS Improvement has identiﬁed atrial ﬁbrillation in
primary care as a priority area for the health service for
2010/11.
13 From a public health perspective, it is
important to determine whether national policies and
preventive strategies are having an effect on stroke
epidemiology. Perhaps the best data on trends in stroke
come from the Oxfordshire region where data from two
studiesdthe Oxford Community Stroke Project
(1981e1984) and the Oxford Vascular Study
(2002e2004)dwere compared.
3 The results suggested
a decline in the incidence of stroke (p¼0.0002) in
association with increased use of preventive treatments
and reduction in risk factors.
There has been no study looking at trends in stroke
across the UK. We report an analysis of the General
Practice Research Database (GPRD) used to investigate
trends in the burden of stroke between 1999 and 2008.
DESIGN
Objectives
The objectives of this study were (1) to investigate recent
trends in the epidemiology of stroke in the UK,
including risk factors associated with ﬁrst and second
strokes, and pharmacological therapies prescribed
before and following a ﬁrst stroke, and (2) to examine
the trend in stroke fatality and the occurrence of
a second stroke following survival of a ﬁrst stroke.
Data source
The GPRD is a database of longitudinal patient primary
care records, containing anonymised data on demo-
graphics, diagnoses, referrals, prescribing and health
outcomes for patients from almost 500 general practi-
tioner (GP) practices in the UK (over 3 million patients).
The database covers approximately 6% of UK patients,
and the geographical distribution is representative of the
UK population.
14 Validation studies have conﬁrmed the
high data quality and completeness of clinical records
within the GPRD.
15e17 A recent systematic literature
review of studies using the GPRD reported that the
median proportion of diagnoses correctly coded
was 89%.
17
Population
We identiﬁed patients aged 18 years and older who had
a ﬁrst stroke between 1999 and 2008. Stroke events were
identiﬁed by a diagnosis for stroke within the patient
record. The Read codes used by GPs to enter a stroke
into a patient record do not necessarily specify the type
of stroke, so we were not able to distinguish between
ischaemic and haemorrhagic strokes. The codes used are
shown in the online supplementary material. Stroke
codes used were those which described acute stroke
events onlydany codes for monitoring or stroke reha-
bilitation were excluded to ensure that we correctly
identiﬁed the initial stroke event and did not record
follow-up of the same stroke as a secondary stroke event.
We excluded patients if they had any coded cardio-
vascular disease event (including coronary heart disease
or peripheral vascular disease) recorded prior to stroke,
except patients with a record of transient ischaemic
attack.
Analysis
Data were extracted using the GPRD GOLD online
version and analysed using SAS V.9.02. The incidence
and prevalence of stroke were calculated based on our
stroke cohort and the total study population extracted
from GPRD.
Co-morbidities were identiﬁed using Read codes (see
online supplementary material). In addition to coded
diagnosis, a blood pressure result above 160/
100 mm Hg was deﬁned as hypertension and a choles-
terol level above 5 mmol/l (193 mg/dl) was deﬁned as
hypercholesterolaemia. Pharmacological therapies
prescribed in the year before the ﬁrst stroke were
recorded. We assumed that patients were treated with
a medication if they received at least two prescriptions
for that medication in the year prior to ﬁrst stroke.
For follow-up, patient data were available from the
time of ﬁrst stroke until the end of the study period or
when the patient transferred out of the practice or died.
Stroke events were considered fatal if patients had
a death coded in their GP record within 56 days of the
stroke. This timescale was used to allow for any delay
between the death occurring and the GP receiving
notiﬁcation of the death and entering it into their
coding system.
Second cardiovascular disease events were deﬁned as
a second stroke or other cardiovascular disease event
(coronary heart disease or peripheral vascular disease
event) occurring more than 56 days after a ﬁrst stroke. A
life table survival analysis was carried out, with an event
deﬁned as either a second cardiovascular event or death.
Patients were censored if they transferred out of the
practice or reached the end of the study period.
We examined trends in the proportion of patients
treated with different classes of pharmacological agents
in the year before and after ﬁrst stroke between 1999
and 2008. For patients with GP-coded atrial ﬁbrillation
(AF) prior to ﬁrst stroke, we calculated CHADS2 scores
9
and recorded use of anticoagulants and antiplatelet
drugs for patients by CHADS2 score in the year prior to
and after ﬁrst stroke.
RESULTS
Between 1999 and 2008, ﬁrst strokes were recorded in
32151 patients with no previous recorded cardiovascular
event. Over this period, stroke incidence fell by 30%,
from 1.48/1000 person-years in 1999 to 1.04/1000
person-years in 2008 (p<0.001). In patients aged
80 years and over (the group at highest risk), incidence
fell by 42% from 18.97 to 10.97/1000 person-years
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Stroke in the UK General Practice Research Database(p<0.001). Prevalence of stroke increased by 12.5% over
the same period from 6.4/1000 persons to 7.2/1000
persons (p<0.001) (ﬁgure 1).
Table 1 shows the baseline characteristics of the
cohort. The average age at ﬁrst stroke was 77 years in
women and 71 years in men. The most commonly coded
stroke risk factor was hypertension, recorded in 65% of
patients. In addition, 12% of patients were coded as
diabetic, and 11% had coded AF.
Fifteen per cent (4926/32151) of ﬁrst strokes were
fatal (death coded within 56 days). Mortality was 18.6%
(3301 of 17792) in women and 11.3% (1625 of 14359)
in men. Age-adjusted to the 2008 UK population,
10 the
mortality difference was smaller but remained higher in
women (6.8%) than men (5.5%) (p<0.001 for differ-
ence between genders). Crude mortality after incident
stroke decreased from 21% in 1999 to 12% in 2008
(p<0.0001). This trend was seen in both men and
women (ﬁgure 2).
Five-year survival was 82% (11774/14359) in men and
81% (14411/17792) in women. Life table survival
analysis showed that survival free of a second cardiovas-
cular event (recurrent stroke or ﬁrst CHD event) at
5 years was 74% (23766/32151) and similar in men and
women. After ﬁrst stroke, patients were at high risk of
a recurrent event. Of patients followed up for 5 years,
24% (3316 of 13599) had a second cardiovascular event;
75% of second events (2475) were strokes and 16% of
these (385) were fatal within 56 days.
Stroke risk factors and management
Sixty-ﬁve per cent of patients (n¼20959) had hyper-
tension. Of these, 67% were treated with antihyperten-
sives in the year prior to stroke (69% of female and 64%
of male patients).
Prescription of treatment for cardiovascular risk
reduction in the year prior to a ﬁrst stroke increased
over time (ﬁgure 3A). A similar trend was seen in
prescriptions after the ﬁrst stroke (ﬁgure 3B). By 2008,
96.6% of women and 97.4% of men with coded hyper-
tension in the year after stroke were receiving antihy-
pertensive therapy.
Before ﬁrst stroke, 38.7% of patients (n¼12440) had
hypercholesterolaemia; 8.7% were treated with lipid
lowering drugs in 1999, rising to 37.6% in 2008.
Prescriptions for lipid lowering drugs after a ﬁrst stroke
also increased rapidly over the last 10 years (ﬁgure 3).
Eleven per cent of patients (n¼3483) had coded AF
before their ﬁrst stroke: 10% of male patients and 12%
of female patients (table 1). These patients were older
than the general stroke cohort. The average age in the
AF group at the time of ﬁrst stroke was 82 years for
women and 77 years for men. Stroke mortality was
higher in patients with coded AF than for the overall
cohort: 27% of women and 19% of men with AF died
within 56 days of their ﬁrst stroke. For those over the age
of 70 years, 56-day mortality after ﬁrst stroke was 32% in
men with coded AF compared with 23% in men without
coded AF (p<0.001), and 36% in women with coded AF
compared with 28% in women without coded AF
(p<0.001).
Women were at higher risk, with 59% having
a CHADS2 score of 2 or above prior to ﬁrst stroke
compared with 42% of men. When we excluded age
from the CHADS2 calculation, women still scored higher
than men: 67% of women and 59% of men had a score
of 1 or above, and 18% of women and 16% of men had
a score of 2 or above.
Of patients with coded AF, 25% (876) were prescribed
anticoagulants before their stroke (22% of women and
29% of men). Anticoagulant prescribing did not
increase with increasing CHADS2 score prior to stroke
(ﬁgure 4). Antiplatelet therapy was prescribed to 52% of
patients with coded AF (1796/3483) (54% of women
and 47% of men) and prescribing increased steeply with
increasing CHADS2 score.
For patients with coded AF at the time of ﬁrst stroke,
anticoagulant prescribing increased from 22% prior to
stroke to 35% after stroke for women, and from 29% to
48% for men (table 2). In patients aged 80 and older,
anticoagulant prescribing increased from 18% to 23% in
women and from 24% to 34% in men.
CONCLUSION
Summary of main ﬁndings
Our study shows that the incidence of stroke in the UK
fell by 29% between 1999 and 2008. The 56-day mortality
after a ﬁrst stroke fell by 43% between 1999 and 2008.
Figure 1 Incidence (A) and
prevalence (B) of stroke in the UK
adult population by age group.
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Stroke in the UK General Practice Research DatabasePrimary care management of cardiovascular risk has
improved, with the majority of recorded hypertension
being controlled prior to stroke, and a rapid increase in
prescriptions for lipid lowering drugs to patients with
diagnosed hypercholesterolaemia. However, there is
a clear suggestion that risk stratiﬁcation is not yet
optimal, particularly in relation to patients with AF.
Comparison with existing literature
A fall in stroke incidence similar to that shown in our
study has previously been reported in Oxfordshire
3 and
south London.
18 Our ﬁndings are also in line with data
from some other high-income countries, with Feigin et al
reporting a 42% decrease in age-adjusted stroke inci-
dence rates over 4 decades to 2008.
19
The observed reduction in stroke incidence is likely to
be related to better control of vascular risk factors both
prior to and following a stroke. By the end of the study
period, GPs were treating cardiovascular risk factors
much more aggressively than in 1999. A previous study
3
reported a trend to reduced incidence of stroke in
association with increased use of preventive treatments
and reduction in risk factors. Our data show improve-
ment compared with a previous analysis of GPRD data
(1997e2006) in which only 75% of patients with diag-
nosed hypertension were receiving antihypertensive
therapy 90 days after incident stroke.
20 In our study, 97%
of patients with hypertension after stroke were receiving
antihypertensive therapy.
Improved primary care management of risk factors
presumably reﬂects national initiatives to reduce
cardiovascular disease. These include the Quality and
Outcomes Framework whereby GPs in England are
incentivised to improve intervention on cardiovascular
risk factors. The increased level of prescribing seen in
our study is in line with a national increase in the use of
statins
21 and improved treatment of hypertension.
22
AF is an important risk factor for stroke, but recent
reports have highlighted that it is both under-recognised
and under-treated.
21 23 Our study conﬁrms that such
individuals have a higher mortality risk after ﬁrst stroke
than patients in sinus rhythm.
The CHADS2 scoring system
24 is commonly used
to assess stroke risk in patients with AF and help
guide thromboprophylaxis. In our study, anticoagulant
prescribing before stroke in patients with AF increased
only slightly between 1999 and 2008. Use of anticoagu-
lants appeared to be unrelated to the patient’s CHADS2
score, as has been reported previously.
25 There was
a relatively high, and possibly inappropriate, level of
anticoagulant prescribing in lower risk patients (those
with a CHADS2 score of 0) and no increase in the use of
anticoagulants with increasing stroke risk. The ﬁnding of
high use of anticoagulants in AF patients at low risk of
stroke has been reported previously in primary care in
the UK.
25
Contrary to data from a previous study using GPRD,
25
we found that antiplatelet prescribing increased signiﬁ-
cantly with increasing CHADS2 score, indicating that
GPs might be responding to increasing thromboembolic
risk by prescribing an antiplatelet agent rather than an
anticoagulant. Use of anticoagulants was lower in women
than men despite women’s higher CHADS2 scores.
Figure 3 Pharmaceutical
therapies prior to ﬁrst stroke (A)
and in the year following ﬁrst
stroke (B).
Figure 2 Stroke mortality within 56 days of ﬁrst stroke by age
group.
Figure 4 Percentage of GP-coded AF patients treated with
anticoagulant and antiplatelet therapy prior to stroke by
CHADS2 score. AF, atrial ﬁbrillation; GP, general practitioner.
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Stroke in the UK General Practice Research DatabaseWomen were older than men in the AF patient popula-
tion and lower use of anticoagulants might reﬂect
prescriber concerns that anticoagulants are more
dangerous in the elderly. However, it has been shown
that there is no signiﬁcant difference in bleeding risk
between warfarin and aspirin in patients aged over
75 years.
26 The lower use of anticoagulants in women
might also reﬂect ﬁndings from other areas of cardio-
vascular disease that women are treated less aggressively
with drug therapy than men.
27 28
Limitations of the study
We are reliant on the quality of GP coding in the GPRD
dataset. There may be some coding error and misre-
porting of cardiovascular events and risk factors.
The GPRD has quality criteria for practices involved
in the data collection and we used data only from such
‘up-to-standard’ practices. A recent systematic review of
the validity of diagnostic coding within GPRD reported
high positive predictive values (>80%) for events such as
myocardial infarction or stroke, but a lower value for AF
(64.4%).
16
Despite an observed difference in risk factors between
men and women in our cohort, we are not able to eval-
uate gender difference in the risk of secondary stroke,
due to the potential confounding factor of age; female
patients were older than male patients. As the objectives
of this study were purely descriptive, we did not make
any adjustments for confounding factors. Further studies
are needed to examine gender differences in stroke risk
and prevention.
Implications for clinical practice
This is the ﬁrst UK-wide study to investigate recent
trends in stroke and it shows an encouraging reduction
in the incidence of ﬁrst stroke and improving survival.
This is likely to be due (at least partially) to much better
identiﬁcation of vascular risk and the prescription of
preventive therapies prior to, and after, stroke. Despite
these positive ﬁndings, there are some areas where
management appears to remain suboptimal. Women are
less well treated than men, perhaps due to an age bias.
Patients with AF, who do particularly poorly after stroke,
do not appear to be appropriately risk stratiﬁed for
anticoagulation therapy. Improved detection of AF and
thromboprophylaxis in such patients should be a priority
for healthcare systems.
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